Graves'病患者促甲状腺素受体抗体和甲状腺刺激免疫球蛋白水平的变化及临床意义

Clinical significance and changes of TRAb and TSI assay in patients with Graves' disease

  • 摘要: 目的 探讨Graves'病患者促甲状腺素受体抗体(TRAb)和甲状腺刺激免疫球蛋白(TSI)水平的变化及临床意义。方法 对正常对照组、Graves'病发作组及缓解组、桥本甲状腺炎组分别进行TRAb、TSI及甲状腺功能检测,其中抗体检测采用酶联免疫法或放射免疫法,甲状腺功能检测采用微粒子发光技术。结果 Graves'发作组TRAb、TSI阳性率分别为86.67%和95.00%,桥本甲状腺炎组甲状腺球蛋白抗体(TGA)和甲状腺微粒体抗体(TMA)维持较高水平。阳性率分别达到85.29%和91.18%。与正常对照组比较均有显著性差异。结论 TRAb、TSI、TGA和TMA联合检测,结合甲状腺功能指标。对Graves'病的疗效监测和预后判断有着非常重要的使用价值,并对与桥本甲状腺炎病的鉴别诊断起着很重要的作用。

     

    Abstract: Objective To explore the changes and clinical significance Of TRAb and TSI detection in patients with Graves' disease. Methods Serum TRAb and TSI levels were detected by enzyme-linked immunesorbent assay, and thyroid hormone levels were detected by micropaticle enzyme immuneoassay, including normal controls, Graves' disease in period of onset catabsis group and hashimotos thyroiditis group. Results The positive rate of TRAb and TSI in Graves' in period of onset group is 86.67% and 95.0%, TGA and TMA in hashimotes thyroiditis group is 85.29% and 91.18%, respectively. More importantly these results were significant difference than normol controls. Conclusions It's very important for Graves' disease patients to detect TRAb, TSI, TGA, TMA and thyroid hormone simulta-neously, especially to the curative effect and prognosis criterin in patients with Graves' disease and antidi-astole in patients with hashimotos thyroiditis.

     

/

返回文章
返回